Are you or a loved one battling severe asthma and relying on steroids? If so, you're likely familiar with the double-edged sword: steroids can offer relief, but prolonged use comes with serious risks. But what if there was a way to manage your asthma while significantly reducing your dependence on these medications? That's precisely what the WAYFINDER trial, presented at the CHEST 2025 Annual Meeting, explored.
The results are truly remarkable: nearly 90% of adult patients with severe, steroid-dependent asthma were able to lower their oral corticosteroid dose to 5 mg or less daily while maintaining control of their asthma symptoms after being treated with tezepelumab. What's more, the number of patients with well-controlled asthma increased dramatically – a staggering 9-fold increase, from a mere 3.0% at the start of the study to 26.9% by the end.
This is a significant breakthrough for those with severe asthma who haven't found relief with conventional treatments and are stuck using steroids. The dangers of long-term steroid use are well-documented, including bone loss, metabolic problems, and a weakened immune system. Finding ways to reduce or eliminate steroids is a critical need in managing severe asthma.
So, how does tezepelumab work its magic? This medication is a human monoclonal antibody that targets thymic stromal lymphopoietin (TSLP). This protein sits at the top of the inflammatory cascade in asthma. By blocking TSLP, tezepelumab tackles multiple inflammatory pathways simultaneously. This is different from other biologics that target specific downstream mediators like IgE or interleukins.
Tezepelumab is approved as an add-on maintenance therapy for adults and adolescents (aged 12 and older) with severe asthma and chronic rhinosinusitis with nasal polyps (CRSwNP) whose asthma isn't well-controlled with their current treatments.
Let's dive into the WAYFINDER trial. Led by Professor David Jackson, this open-label, single-arm, multicenter phase 3b trial involved 298 adults with severe asthma. These participants needed maintenance oral corticosteroids (prednisone or prednisolone) at doses ranging from 5–40 mg/day for at least 3 months before the trial. They received subcutaneous tezepelumab (210 mg) every 4 weeks for up to 52 weeks.
The trial involved a 4-week phase where steroid doses were kept stable, followed by a 48-week period where doses were gradually reduced and then maintained. Steroid tapering was done carefully, with reductions of less than 5 mg per day, depending on how well the adrenal glands were functioning.
The results are compelling. At the beginning of the study, patients were taking an average maintenance oral corticosteroid dose of around 10.8 mg daily. By week 28, a remarkable 88.9% of the participants had reduced their dose to 5 mg or less per day, and this remained consistent at 89.9% through week 52. What's more, 82.2% of those who achieved the lower maintenance dose maintained asthma control at week 52, even after adjusting for systemic corticosteroid use related to adrenal insufficiency.
The impact on asthma control was also significant. At the start of the study, 80.2% of participants had uncontrolled asthma, which dropped to 34.9% by week 52. The average Asthma Control Questionnaire-6 score improved from 2.6 at the start to 1.5 at week 28 and 1.4 at week 52, indicating a real improvement in symptoms. By the end of the trial, 47.3% of participants had achieved at least partially controlled asthma. The safety profile of tezepelumab was consistent with previous trials.
But here's where it gets controversial: Earlier clinical trials had mixed results. The SOURCE study didn't meet its main goal of significantly reducing OCS use without loss of asthma control. However, a subgroup analysis showed it worked well in patients with high eosinophil counts. The subsequent DESTINATION trial, which followed patients for 104 weeks, showed that 66.7% of tezepelumab-treated patients stopped using OCS, compared to 46.9% in the placebo group. This led to the more successful WAYFINDER study.
As the treatment options for severe asthma grow, tezepelumab, with its unique way of targeting TSLP, is becoming a valuable option, particularly for patients who haven't responded to standard treatments. The WAYFINDER results support its use in personalized respiratory care, focusing on both improving the disease and reducing harm.
What do you think? Are you or someone you know dealing with severe asthma? Have you found success with tezepelumab or other treatments? Share your experiences and thoughts in the comments below!
